pov3-21

ONCOLOGY
BULLETIN
OF THE VOLGA REGION Vol. 12, no. 3. 2021
Science. — 1994. — 266 (5182). — P. 66-71.
https://doi.org/10.1126/science.7545954
13. Wooster R., Neuhausen S.L., Mangion J., et al.
Localization of a breast cancer susceptibility
gene, BRCA2, to chromosome 13q12-13 //
Science. — 1994. — 265 (5181). — P. 2088-2090.
https://doi.org/10.1126/science.8091231
14. Balmaña J., Díez O., Rubio I.T., Cardoso, F., & ESMO
Guidelines Working Group. BRCA in breast cancer:
ESMO Clinical Practice Guidelines // Annals of
oncology: official journal of the European Society
for Medical Oncology. — 2011. — 22 Suppl 6. —
P. vi31-vi34. https://doi.org/10.1093/annonc/mdr373
15. Berx G., Becker K.F., Höfler H. et al. Mutations of
the human E-cadherin (CDH1) gene // Human
mutation. — 1998. — 12 (4). — P. 226-237.
https://doi.org/10.1002/(SICI)1098-
1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D
16. Brooks-Wilson A.R., Kaurah P., Suriano G.,
et al. Germline E-cadherin mutations in hereditary
diffuse gastric cancer: assessment of 42 new families
and review of genetic screening criteria // Journal of
medical genetics. — 2004. — 41 (7). — P. 508-517.
https://doi.org/10.1136/jmg.2004.018275
17. Johannsson O., Loman N., Möller T., et al. Incidence
of malignant tumours in relatives of BRCA1 and
BRCA2 germline mutation carriers // European
journal of cancer. — 1999. — 35 (8). — P. 1248-1257.
https://doi.org/10.1016/s0959-8049(99)00135-5
18. Bang Y.J., Van Cutsem E., Feyereislova A.,
et al. Trastuzumab in combination with
chemotherapy versus chemotherapy alone for
treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA):
a phase 3, open-label, randomised controlled trial //
The Lancet. — 2010. — 376 (9742). — P. 687-697.
https://doi.org/10.1016/S0140-6736(10)61121-X
19. Wilke H., Muro K., Van Cutsem E., et al. Ramucirumab
plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric
or gastro-oesophageal junction adenocarcinoma
(RAINBOW): a double-blind, randomised phase 3 trial //
The Lancet. Oncology. — 2014. — 15 (11). — P. 1224-
1235. https://doi.org/10.1016/S1470-2045(14)70420-6
20. Xue J.M., Astère M., Zhong M.X., et al. Efficacy and safety
of apatinib treatment for gastric cancer, hepatocellular
carcinoma and non-small cell lung cancer: a metaanalysis
// OncoTargets and therapy. — 2018. — 11. —
P. 6119-6128. https://doi.org/10.2147/OTT.S172717
21. Xiaoting Lin, Dongshao Chen, Cheng Zhang, et al.
Augmented antitumor activity by olaparib plus
AZD1775 in gastric cancer through disrupting
DNA damage repair pathways and DNA damage
checkpoint // Journal of Experimental & Clinical
Cancer Research. — 2018. — 37. — P. 129.
https://doi.org/10.1186/s13046-018-0790-7.
22. Lin K.Y., & Kraus W.L. PARP Inhibitors for Cancer
Therapy // Cell. — 2017. — 169 (2). — P. 183.
https://doi.org/10.1016/j.cell.2017.03.034
23. Kaufman B., Shapira-Frommer R., Schmutzler R.K., et al.
Olaparib monotherapy in patients with advanced
cancer and a germline BRCA1/2 mutation // Journal
of clinical oncology: official journal of the American
Society of Clinical Oncology. — 2015. — 33 (3). —
P. 244-250. https://doi.org/10.1200/JCO.2014.56.2728
24. Mateo J., Carreira S., Sandhu S., et al. DNA-
Repair Defects and Olaparib in Metastatic
Prostate Cancer // The New England journal of
medicine. — 2015. — 373 (18). — P. 1697-1708.
https://doi.org/10.1056/NEJMoa1506859
25. Clarke N., Wiechno P., Alekseev B., et al. Olaparib
combined with abiraterone in patients with metastatic
castration-resistant prostate cancer: a randomised,
double-blind, placebo-controlled, phase 2 trial // The
Lancet. Oncology. — 2018. — 19 (7). — P. 975-986.
https://doi.org/10.1016/S1470-2045(18)30365-6
26. Mateo J., Porta N., Bianchini D., et al. Olaparib in
patients with metastatic castration-resistant prostate
cancer with DNA repair gene aberrations (TOPARP-B):
a multicentre, open-label, randomised, phase 2 trial //
The Lancet. Oncology. — 2020. — 21 (1). — P. 162-174.
https://doi.org/10.1016/S1470-2045(19)30684-9
27. Fok J., Ramos-Montoya A., Vazquez-Chantada
M., et al. AZD7648 is a potent and selective
DNA-PK inhibitor that enhances radiation,
chemotherapy and olaparib activity // Nature
communications. — 2019. — 10 (1). — P. 5065.
https://doi.org/10.1038/s41467-019-12836-9
28. Deben C., Lardon F., Wouters A., et al. APR-246
(PRIMA-1(MET)) strongly synergizes with AZD2281
(olaparib) induced PARP inhibition to induce
apoptosis in non-small cell lung cancer cell lines //
Cancer letters. — 2016. — 375 (2). — P. 313-322.
https://doi.org/10.1016/j.canlet.2016.03.017
29. Wang H., Zou L., Ma K., et al. Cell-specific mechanisms of
TMEM16A Ca 2+ -activated chloride channel in cancer //
Molecular cancer. — 2017. — 16 (1). — P. 152.
https://doi.org/10.1186/s12943-017-0720-x
30. Mohr C.J., Steudel F.A., Gross D., et al. Cancer-
Associated Intermediate Conductance Ca 2+ -Activated
K+ Channel K Ca
3.1 // Cancers. — 2019. — 11 (1). — P. 109.
https://doi.org/10.3390/cancers11010109
31. Okada Y., Okada T., Sato-Numata K., et al. Cell Volume-
Activated and Volume-Correlated Anion Channels
in Mammalian Cells: Their Biophysical, Molecular,
and Pharmacological Properties // Pharmacological
reviews. — 2019. — 71 (1). — P. 49-88.
https://doi.org/10.1124/pr.118.015917
32. Rohrbough J., Nguyen H.N., & Lamb F.S. Modulation of
ClC-3 gating and proton/anion exchange by internal
and external protons and the anion selectivity filter //
The Journal of physiology. — 2018. — 596 (17). —
P. 4091-4119. https://doi.org/10.1113/JP276332
33. Jentsch T.J., & Pusch M. CLC Chloride Channels
and Transporters: Structure, Function,
Physiology, and Disease // Physiological
reviews. — 2018. — 98 (3). — P. 1493-1590.
https://doi.org/10.1152/physrev.00047.2017
Clinical research
31